FAERS: how the FDA tracks drug side effects after approval
The FDA's safety database collects reports long after a drug reaches pharmacy shelves — here is how that system works and where its limits lie.
TL;DR
- FAERS is the FDA's postmarketing surveillance database, collecting drug side-effect reports from patients, clinicians, and manufacturers.
- Anyone can search the FAERS Public Dashboard, but a report does not prove the drug caused the event.
- Gray-market products have no equivalent reporting system, which is a real blind spot for patients and regulators alike.
What is faers
FAERS — the FDA Adverse Event Reporting System — is the FDA's computerized database for postmarketing surveillance (in plain English: watching for safety problems after a drug is already on the market). When a new drug clears clinical trials and wins approval, the trials cover thousands of people at most. FAERS exists because rare side effects that appear in one in ten thousand patients may not show up until millions of people have used the drug. The FDA operates FAERS to catch those signals. (FDA Adverse Event Reporting System — FDA, 2024)
Reports are coded using MedDRA terms — MedDRA (Medical Dictionary for Regulatory Activities) is a standardized vocabulary that lets the FDA compare reports across languages and reporting formats. Analysts then screen the coded data for unexpected clusters of adverse events (in plain English: patterns that suggest a drug may be causing harm at a rate higher than expected).
How does the fda track adverse events
The primary intake channel is MedWatch, the FDA's reporting portal launched in 1993. It accepts reports from three groups: healthcare professionals (voluntary), consumers and patients (voluntary), and drug manufacturers (mandatory — companies must forward any reports they receive within strict timeframes). (MedWatch: Your Report Can Make a Difference — FDA, 2023)
Think of MedWatch as a neighborhood tip line. Anyone can call in. Each call is logged and coded. Analysts look for patterns — not individual tips. A single report of a headache after taking a drug does not trigger a recall. But five hundred reports of the same rare liver finding in six months might start a formal pharmacovigilance (in plain English: drug safety monitoring) investigation.
What is the faers public dashboard
The FAERS Public Dashboard is a free, searchable tool hosted by the FDA. Anyone — clinician, journalist, patient, researcher — can enter a drug name and pull counts of adverse event reports submitted for that product. This transparency is intentional. The FDA wants the data to be accessible.
The critical caveat is baked into every FAERS search: a report is not proof of causation. The data is voluntary and therefore incomplete. Reports are not clinically verified. A patient who took five medications and reported a side effect may have only listed one. This means raw counts from FAERS can easily mislead if read without context. Researchers use statistical disproportionality analysis — not raw counts — to find real signals in the data.
The connection to compounded and gray-market products is direct. Approved drugs feed into FAERS. Compounded products and gray-market alternatives do not have the same reporting pathway, which means safety signals for those products are far less visible to regulators.
Related reading:
- FDA import alerts: why ordering peptides from overseas is risky
- FDA-approved peptide drugs vs gray-market peptides
- The ProPublica peptide safety story: what it got right and wrong
- Category 2 peptides: what the access limits mean for patients
- How a peptide becomes a prescription medication
FAQ
Q: What is FAERS? FAERS (FDA Adverse Event Reporting System) is the FDA's computerized database for postmarketing safety surveillance — collecting reports of side effects and medication errors after a drug is on the market. Reports come from clinicians, patients, and manufacturers.
Q: How does the FDA track adverse events? The FDA collects adverse event reports through MedWatch, its voluntary reporting portal launched in 1993. Manufacturers are legally required to forward reports they receive. Incoming reports are coded with standardized MedDRA terms and screened for emerging safety signals.
Q: What is the FAERS Public Dashboard? The FAERS Public Dashboard is a free, searchable online tool that lets anyone look up adverse event reports submitted for any drug. A key limitation: a report in FAERS does not prove the drug caused the event — data is voluntary, incomplete, and unverified.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
Frequently asked questions
What is FAERS?
FAERS (FDA Adverse Event Reporting System) is the FDA's computerized database for postmarketing safety surveillance — collecting reports of side effects and medication errors after a drug is on the market. Reports come from clinicians, patients, and manufacturers.
How does the FDA track adverse events?
The FDA collects adverse event reports through MedWatch, its voluntary reporting portal launched in 1993. Manufacturers are legally required to forward reports they receive. Incoming reports are coded with standardized MedDRA terms and screened for emerging safety signals.
What is the FAERS Public Dashboard?
The FAERS Public Dashboard is a free, searchable online tool that lets anyone look up adverse event reports submitted for any drug. A key limitation: a report in FAERS does not prove the drug caused the event — data is voluntary, incomplete, and unverified.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.